Edition:
India

Anika Therapeutics Inc (ANIK.OQ)

ANIK.OQ on NASDAQ Stock Exchange Global Select Market

40.81USD
1:30am IST
Change (% chg)

$-0.59 (-1.43%)
Prev Close
$41.40
Open
$41.52
Day's High
$41.52
Day's Low
$40.16
Volume
20,018
Avg. Vol
59,478
52-wk High
$68.57
52-wk Low
$28.54

Latest Key Developments (Source: Significant Developments)

Anika Announces FDA 510(K) Clearance For Its Injectable HA-Based Bone Repair Treatment
Wednesday, 27 Dec 2017 

Dec 27 (Reuters) - Anika Therapeutics Inc ::ANIKA ANNOUNCES FDA 510(K) CLEARANCE FOR ITS INJECTABLE HA-BASED BONE REPAIR TREATMENT.ANIKA THERAPEUTICS INC - HA-BASED BONE VOID FILLER RECEIVED 510(K) CLEARANCE FROM U.S. FDA.  Full Article

Anika reports Q3 earnings per share $0.46
Thursday, 26 Oct 2017 

Oct 25 (Reuters) - Anika Therapeutics Inc ::Anika reports third quarter 2017 financial results.Q3 earnings per share $0.46.Q3 revenue rose 5 percent to $27.2 million.  Full Article

Anika completes enrollment in second pivotal phase III trial of cingal
Thursday, 26 Oct 2017 

Oct 25 (Reuters) - Anika Therapeutics Inc ::Anika completes enrollment in second pivotal phase iii trial of cingal for the treatment of knee pain associated with osteoarthritis.Anika completes enrollment in second pivotal phase iii trial of cingal for the treatment of knee pain associated with osteoarthritis.Anika Therapeutics - ‍Anika expects to complete cingal second pivotal phase III trial in first half of 2018 and anticipates FDA approval following year​.  Full Article

Anika Therapeutics announces regulatory approval for Monovisc® in Australia
Tuesday, 17 Oct 2017 

Oct 17 (Reuters) - Anika Therapeutics Inc :Anika announces regulatory approval for Monovisc® in Australia for the treatment of pain associated with osteoarthritis of all synovial joints.Anika Therapeutics Inc - ‍Anika intends to further expand Monovisc into additional international markets in 2018​.  Full Article

Anika Therapeutics posts Q4 earnings per share $0.54
Thursday, 16 Feb 2017 

Anika Therapeutics Inc : Anika reports fourth quarter and full year 2016 financial results . Q4 earnings per share $0.54 . Q4 revenue $28.7 million versus I/B/E/S view $27.8 million . Q4 earnings per share view $0.53 -- Thomson Reuters I/B/E/S . Expects total revenue growth to be in mid-teen percentage range for full year of 2017 .Licensing, milestone and contract revenue is expected to be $5 million for year.  Full Article

BRIEF-Anika Therapeutics Q1 Loss Per Share $0.46

* Q1 EARNINGS PER SHARE VIEW $0.16 -- THOMSON REUTERS I/B/E/S